Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-27T10:57:06.289Z Has data issue: false hasContentIssue false
  • English
  • Français

Role of p.r.n. antimuscarinic medication in the treatment of antipsychotic-induced extrapyramidal movement disorders

Published online by Cambridge University Press:  02 January 2018

Luke Birmingham ,
Norman McClelland  and
Caroline Bradley
Luke Birmingham*
Affiliation:
Reaside Clinic, Birmingham Great Park, Bristol Road South, Birmingham B45 9BE
Norman McClelland
Affiliation:
Reaside Clinic, Birmingham Great Park, Bristol Road South, Birmingham B45 9BE
Caroline Bradley
Affiliation:
Reaside Clinic, Birmingham Great Park, Bristol Road South, Birmingham B45 9BE
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The antimuscarinic drugs procyclidine, orphenadrine, benzhexol and benztropine are used in psychiatric practice to alleviate the extrapyramidal effects of antipsychotic medication. These drugs may be prescribed on a regular, as-required or single-dose basis. They are usually taken by mouth, in tablet or liquid form, but for rapid onset of action procyclidine and benztropine can be given by intramuscular or intravenous injection.

Type
Drug information quarterly
Information
Psychiatric Bulletin , Volume 23 , Issue 6 , June 1999 , pp. 368 - 369
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 The Royal College of Psychiatrists

References

Bamrah, J. S., Kumar, V., Krska, J., et al (1986) Interactions between procyclidine and neuroleptic drugs. Some pharmacological and clinical aspects. British Journal of Psychiatry, 149, 726 733.Google Scholar
Barnes, T. R. E. & Phillips, M. A. (1996) Antipsychotic-induced extrapyramidal symptoms. Role of anticholinergic drugs in treatment. CNS Drugs, 6, 315 330.Google Scholar
Birmingham, L., McClelland, N. & Bradley, C. (1999) p.r.n. prescribing and administration of antimuscarinic medication. Psychiatric Bulletin, 23, 184 185.Google Scholar
Blaisdell, G. D. (1994) Akathisia. A comprehensive review and treatment summary. Pharmacopsychiatry, 27, 139 146.Google Scholar
Calev, A. (1984) Anticholinergic drugs and memory. British Journal of Psychiatry, 143, 422 423.Google Scholar
Ebel, H. (1994) Therapy of neuroleptic-induced extrapyramidal movement disorders. Neurology, Psychiatry & Brain Research, 2, 140 151.Google Scholar
Holloman, L. C. & Marder, S. R. (1997) Management of acute extrapyramidal effects induced by antipsychotic drugs. American Journal of Health-System Pharmacy, 54, 2461 2477.Google Scholar
Johnson, A. L., Hollister, L. E. & Berger, P. A. (1981) The anticholinergic intoxication syndrome: diagnosis and treatment. Journal of Clinical Psychiatry, 42, 313 317.Google ScholarPubMed
Marken, P. A., Stoner, S. C. & Bunker, M. T. (1996) Anticholinergic drug abuse and misuse. CNS Drugs, 5, 190 199.Google Scholar
Pullen, G. P., Best, N. R. & Maguire, J. (1984) Anticholinergic drug abuse: a common problem? British Medical Journal, 289, 612 613.Google Scholar
World Health Organization Heads of Centres Collaborating in WHO Co-ordinated Studies on Biological Aspects of Mental Illness (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. British Journal of Psychiatry, 156, 412.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.